Belpointe Asset Management
ARCT icon

Belpointe Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Belpointe Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-743
Closed -$12.6K – 3729
2022
Q4 		$12.6K Buy
+743
New +$13K ﹤0.01% 2488

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Belpointe Asset Management's ARCT Position: Q1 2023 in Review

Belpointe Asset Management sold out of Arcturus Therapeutics (ARCT) in Q1 2023, closing a stake of 743 shares — an estimated $12.6K sold.

Belpointe Asset Management first reported a position in ARCT in Q4 2022 and held it in 1 quarter. The position peaked at $12.6K in Q4 2022. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2023.

  • Belpointe Asset Management reported no remaining Arcturus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 743 Arcturus Therapeutics shares in Q1 2023, an estimated $12.6K.
  • Belpointe Asset Management first reported a position in Arcturus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Arcturus Therapeutics position peaked at $12.6K in Q4 2022.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.